20/20 Biolabs, Inc.
Nasdaq · CIK 0001139685 · Fiscal year end 1231
Latest reported period: Latest published period
Revenue
$353,375
Cost Of Revenue
$290,491
Gross Profit
$62,884
Recent financials
| Metric | Current | Prior | Change |
|---|---|---|---|
| Revenue | $353,375 | - | - |
| Cost Of Revenue | $290,491 | - | - |
| Gross Profit | $62,884 | - | - |
| Operating Income | $-1.4M | - | - |
| Net Income | $-2.2M | - | - |
| Eps Basic | -0.28 | - | - |
| Eps Diluted | -0.28 | - | - |
| Cash And Equivalents | $4.2M | - | - |
| Total Assets | $5.8M | - | - |
| Total Liabilities | $3.0M | - | - |
| Shareholders Equity | $2.6M | - | - |
| Operating Cash Flow | $-1.3M | - | - |
Latest filings
| Form | Company | Filed | Accession |
|---|---|---|---|
| 10-Q | 20/20 Biolabs, Inc. | 2026-05-20 | 0001213900-26-059542 |
| S-1 | 20/20 Biolabs, Inc. | 2026-04-06 | 0001213900-26-040553 |
| POS AM | 20/20 Biolabs, Inc. | 2026-04-06 | 0001213900-26-040545 |
| 10-K | 20/20 Biolabs, Inc. | 2026-03-31 | 0001213900-26-037667 |
| 4 | 20/20 Biolabs, Inc. | 2026-02-23 | 0001213900-26-019456 |
| 4 | 20/20 Biolabs, Inc. | 2026-02-23 | 0001213900-26-019424 |
| 4 | 20/20 Biolabs, Inc. | 2026-02-23 | 0001213900-26-019423 |
| 4 | 20/20 Biolabs, Inc. | 2026-02-23 | 0001213900-26-019421 |